T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

Masatomo Kuno, Ayumu Ito, Akiko Miyagi Maeshima, Hirokazu Taniguchi, Takashi Tanaka, Yoshihiro Inamoto, Saiko Kurosawa, Sung Won Kim, Takahiro Fukuda

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Posttransplant lymphoproliferative disorder (PTLD) after allogeneic hematopoietic cell transplantation (HCT) is usually donor derived, associated with Epstein–Barr virus (EBV), and of B-cell origin. T-cell PTLD (T-PTLD) after allogeneic HCT is extremely rare. Four of 1015 (0.39%) allogeneic HCT patients were diagnosed with T-PTLD; peripheral T-cell lymphoma-not otherwise specified, anaplastic large cell lymphoma, monomorphic T-cell PTLD and polymorphic PTLD with chronic active EBV infection-like symptoms. Three of the four patients developed T-PTLD within 6 months after HCT from HLA-mismatched unrelated donor. Three (75%) and 4 (100%) cases were positive for EBV-encoded small RNA in situ hybridization and EBV-DNA load in peripheral blood, respectively. Chimerism analysis showed that 75% of T-PTLD tissues (3/4) were recipient derived. T-PTLD was refractory to salvage chemotherapy and fatal in all four patients. Including the 10 patients in the literature, the median interval from HCT to diagnosis of T-PTLD was 5 months (range 1–72 months), 55% were negative for EBV, and 56% were recipient-derived. T-PTLD, which often occurred early after allogeneic HCT, was more likely to be EBV negative and recipient derived than B-cell PTLD after allogeneic HCT. Like T-PTLD after solid organ transplant, T-PTLD after allogeneic HCT demonstrated morphological heterogeneity and poor prognosis.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalInternational Journal of Hematology
Issue number2
Publication statusPublished - 01-08-2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology


Dive into the research topics of 'T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation'. Together they form a unique fingerprint.

Cite this